Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Apr;96(4):193-5.
doi: 10.1007/s00392-007-0487-y. Epub 2007 Feb 15.

Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?

Iwan C C van der Horst  1 , Adriaan A Voors, Dirk J van Veldhuisen
Affiliations

Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?

Iwan C C van der Horst et al. Clin Res Cardiol. 2007 Apr.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
All-cause mortality in RALES and EPHESUS (adapted from [4] and [5]). Mean follow-up period is 24 months in RALES and 16 months in EPHESUS
Fig. 2
Fig. 2
The risk of sudden cardiac death after myocardial infarction (adapted from [12])
See this image and copyright information in PMC

Comment in

References

    1. Swedberg K, Cleland JG, Dargie H et al (2005) Guidelines for the diagnosis and treatment of chronic heart failure:executive summary (update 2005):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26:1115–1140 - DOI - PubMed
    1. Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675 - DOI - PubMed
    1. Pfeffer MA, Swedberg K, Granger CB et al (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure:the CHARM-Overall programme. Lancet 362(9386):759–766 - DOI - PubMed
    1. Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709–717 - DOI - PubMed
    1. Pitt B, Remme W, Zannad F, Neaton J et al; of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321 - DOI - PubMed

MeSH terms

Substances